SR ONE CAPITAL MANAGEMENT, LLC - 27 Nov 2023 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 27 Nov 2023
Net transaction value: -$369,457
SEC form: 4
Accepted by SEC: 29 Nov 2023, 17:07:06 UTC
Prior SEC filing: 15 May 2023
Next SEC filing: 12 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Sasha Keough, attorney-in-fact for SR One Capital Management, LLC

Key filing fact

SR ONE CAPITAL MANAGEMENT, LLC filed Form 4 for eFFECTOR Therapeutics, Inc. on 29 Nov 2023.

Key facts

This page summarizes SR ONE CAPITAL MANAGEMENT, LLC's Form 4 filing for eFFECTOR Therapeutics, Inc..
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 29 Nov 2023, 17:07.

Change

Previous filing in this sequence was filed on 15 May 2023.
Current net transaction value: -$369,457.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EFTR transaction

Common Stock

Sale

Transaction value: $261,146
Shares: -430,578
Change %: -8.9%
Price: $0.6065
Shares after: 4,391,536
Date: 27 Nov 2023
Ownership: See Note 2
Footnotes: F1, F2

EFTR transaction

Common Stock

Sale

Transaction value: $108,312
Shares: -178,585
Change %: -8.9%
Price: $0.6065
Shares after: 1,821,415
Date: 27 Nov 2023
Ownership: See Note 3
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

SR ONE CAPITAL MANAGEMENT, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5691 to $0.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

The securities are directly held by SR One Capital Fund I Aggregator, LP ("SR One Fund I Aggregator"). SR One Capital Partners I, LP ("SR One Partners I") is the sole general partner of SR One Fund I Aggregator, and SR One Capital Management, LLC ("SR One Capital Management") is the sole general partner of SR One Partners I. Simeon George, M.D. is the managing member of SR One Capital Management (SR One Partners I, SR One Capital Management, and Dr. George together, the "Fund I Indirect Reporting Persons"). The Fund I Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or otherwise of such portion of the securities held by SR One Fund I Aggregator in which the Fund I Indirect Reporting Persons have no pecuniary interest.

Footnote F3

The securities are directly held by SR One Co-Invest I, LLC ("SR One Co-Invest I"). SR One Co-Invest I Manager, LLC ("SR One Co-Invest I Manager") is the managing member of SR One Co-Invest I and SR One Capital Management is the managing member of SR One Co-Invest I Manager. Dr. George is the managing member of SR One Capital Management (SR One Co-Invest I Manager, SR One Capital Management, and Dr. George together, the "Co-Invest I Indirect Reporting Persons"). The Co-Invest I Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 or otherwise of such portion of the securities held by SR One Co-Invest I in which the Co-Invest I Indirect Reporting Persons have no pecuniary interest.